journal article·2020-01-01Open access

Gellable silk fibroin-polyethylene sponge for hemostasis

Wei Wei, Jian Liu, ZhiBin Peng, Min Liang, YanSong Wang, XiaoQin Wang

Abstract

Traditional haemostatic materials generally have slow hemostasis rate and poor biocompatibility. This paper reports on the haemostatic properties and mechanism of silk fibroin (SF). SF-PEG sponge that could be solubilised and changed to gel form by blood was fabricated through mixing SF and polyethylene glycol (PEG, 1500 Da) followed by lyophilisation of the mixed solution. SF-PEG sponge, together with control samples of SF sponge (no PEG) and a commercially available haemostatic material, gelatine sponge, were subjected to the hemostasis tests using a liver trauma model of rabbit. The results showed that SF was superior to gelatine sponge in hemostasis time (136.17 ± 62.27 s and 249.83 ± 29.18 s) and blood loss (2.16 ± 1.27 g vs. 4.97 ± 1.44 g). Furthermore, in vitro experiments indicated SF-PEG sol-gel transition promoted platelet adhesion and aggregation, as well as platelet-fibrinogen interaction. Therefore, except for the physical blocking of bleeding port due to PEG-induced SF fast gelation, SF might also have an impact on blood coagulation process, a phenomenon that has not been reported before. In conclusion, SF is a new type of haemostatic material that might be able to meet the requirements of speed, efficiency and biosafety in a variety of clinical applications.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Silk-based biomaterials and applications · Hemostasis and retained surgical items · Surgical Sutures and Adhesives

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Orthopaedics, The 1st Affiliated Hospital of Harbin Medical University

Department of Orthopaedics, Harbin 242 Hospital

National Engineering Laboratory for Modern Silk, College of Textile and Clothing Engineering, Soochow University

Simatech Incorporation

Funding

the Natural Science Foundation of China Grant

References (43)

Show source-provided references
1. 10.1016/j.biomaterials.2009.06.05210.1016/j.biomaterials.2009.06.052 ↗
2. 10.1097/01.TA.0000127763.90890.3110.1097/01.TA.0000127763.90890.31 ↗
3. 10.1097/01.TA.0000136155.97758.CD10.1097/01.TA.0000136155.97758.CD ↗
4. 10.1097/00005373-200301000-0002310.1097/00005373-200301000-00023 ↗
5. 10.1097/01.ta.0000199392.91772.4410.1097/01.ta.0000199392.91772.44 ↗
6. 10.1016/S0266-4356(97)90689-610.1016/S0266-4356(97)90689-6 ↗
7. 10.1046/j.1423-0410.1997.7230133.x10.1046/j.1423-0410.1997.7230133.x ↗
8. 10.1227/00006123-198407000-0000410.1227/00006123-198407000-00004 ↗
9. 10.1002/jbmr.155810.1002/jbmr.1558 ↗
10. 10.1016/j.polymer.2008.08.00610.1016/j.polymer.2008.08.006 ↗
11. 10.1016/j.progpolymsci.2007.05.01310.1016/j.progpolymsci.2007.05.013 ↗
12. 10.1038/nprot.2011.37910.1038/nprot.2011.379 ↗
13. 10.1002/(SICI)1097-4636(20000605)50:3<344::AID-JBM8>3.0.CO;2-D10.1002/(SICI)1097-4636(20000605)50:3<344::AID-JBM8>3.0.CO;2-D ↗
14. 10.1002/jbm.a.3249710.1002/jbm.a.32497 ↗
15. 10.1016/j.bone.2009.05.02610.1016/j.bone.2009.05.026 ↗
16. Moon BM, Ju HW, Park HJ, et al. The pilot study for the development of the hemostatic agent using silk fibroin for epistaxis. Tissue Eng Regen Med. 2013;10:41–47.
17. 10.1016/j.biomaterials.2007.01.03110.1016/j.biomaterials.2007.01.031 ↗
18. 10.1016/S0142-9612(03)00533-710.1016/S0142-9612(03)00533-7 ↗
19. 10.1023/B:PHAM.0000016235.32639.2310.1023/B:PHAM.0000016235.32639.23 ↗
20. 10.1016/S0049-3848(00)00353-410.1016/S0049-3848(00)00353-4 ↗
21. 10.1016/j.actbio.2014.10.02710.1016/j.actbio.2014.10.027 ↗
22. 10.1002/adhm.20170102610.1002/adhm.201701026 ↗
23. 10.1002/adhm.20150039210.1002/adhm.201500392 ↗
24. 10.1021/bm200062a10.1021/bm200062a ↗
25. 10.1016/j.actbio.2016.05.01910.1016/j.actbio.2016.05.019 ↗
26. 10.1021/acsbiomaterials.8b0045410.1021/acsbiomaterials.8b00454 ↗
27. 10.2165/00003495-199958050-0001010.2165/00003495-199958050-00010 ↗
28. 10.1007/s11595-011-0360-810.1007/s11595-011-0360-8 ↗
29. 10.1016/S0142-9612(96)00137-810.1016/S0142-9612(96)00137-8 ↗
30. 10.1016/S0165-022X(98)00024-410.1016/S0165-022X(98)00024-4 ↗
31. 10.1016/j.ijpharm.2006.07.04310.1016/j.ijpharm.2006.07.043 ↗
32. 10.1016/S0142-9612(01)00189-210.1016/S0142-9612(01)00189-2 ↗
33. 10.1080/1090312070120589310.1080/10903120701205893 ↗
34. 10.1271/bbb.57.191010.1271/bbb.57.1910 ↗
35. 10.1021/jp056350v10.1021/jp056350v ↗
36. 10.1038/nature0180910.1038/nature01809 ↗
37. 10.1016/j.biomaterials.2008.07.04110.1016/j.biomaterials.2008.07.041 ↗
38. 10.1021/bm034546010.1021/bm0345460 ↗
39. 10.1248/cpb.43.28410.1248/cpb.43.284 ↗
40. 10.1016/j.bpj.2009.07.02810.1016/j.bpj.2009.07.028 ↗
41. 10.1016/j.biomaterials.2007.11.00310.1016/j.biomaterials.2007.11.003 ↗
42. 10.1002/adma.20080210610.1002/adma.200802106 ↗
43. 10.1038/nm109810.1038/nm1098 ↗